World-class leader in community-based oncology research
Numbers at-a-glance
1,300+
oncology physicians providing access to clinical trials across multiple tumor types in SCRI’s research network
250+
locations across 24 states in the U.S., reaching 1 in 5 patients with cancer
1,000+
clinical trials actively enrolling patients
4,500+
registered patients participating in clinical trials annually
800+
first-in-human clinical trials conducted to date since SCRI’s inception
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. As a leader in drug development, SCRI is at the forefront of bringing cutting-edge therapies to community clinicians and patients close to home.
We offer:
- End-to-end clinical trial site management all in one place – from our contract research organization (CRO) SCRI Development Innovations
- Centralized clinical trial support services through our site management organization (SMO)
- Personalized Medicine program that transforms real-world data into actionable insights
- Services to improve clinical trial diversity and access
Our academically-trained clinical researchers are key opinion leaders in oncology and experts in their disease sites. They serve as investigators for clinical trials across various solid tumor and hematologic malignancies, provide expertise across SCRI’s research network in the U.S. and connect via SCRI’s executive disease site research committees.
Our research network reaches 1 in 5 patients with cancer.
Since its inception, SCRI has partnered with leading biopharmaceutical companies to conduct community-based clinical research in oncology – from early to late-stage clinical trial development – in hundreds of communities across the U.S. We have contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA. Our expansive research network reaches 1 in 5 patients with cancer in the U.S. through our affiliated sites and brings together more than 1,300 oncology physicians who are actively enrolling patients into clinical trials at more than 250 locations across 24 states in the U.S. We provide access to more than 1,000 active clinical trials.
We help biopharma partners accelerate drug development & enhance clinical trial delivery.
Our partners benefit from Accelero, our Accelerated Operations Model, which maximizes all functions of SCRI to accelerate drug development and optimize clinical trial delivery. Coordinated through our CRO, SCRI Development Innovations, Accelero enhances connectivity to SCRI research sites, which in turn maximizes site contributions, optimizes site activation timelines, and synchronizes end-to-end clinical research management.
Through SCRI’s Personalized Medicine program and integration with Genospace, Accelero works with biopharma partners to seamlessly integrate data from the Electronic Health Record (EHR) to the Electronic Data Capture (EDC), EHR2EDC (E2E) systems for clinical trial data collection. By efficiently expanding access to clinical research in the community, we help our partners achieve their ultimate goal of bringing new oncology therapies to patients close to home.
